To explore whether down-regulation of MUS81 expression in gastric cancer cells affected the antitumoral efficacy of PARP inhibitors, MTS assay was performed and the data were analyzed to construct the dose-inhibition efficiency curves of the PARP inhibitor talazoparib in different groups. This evidence concerns the gene MUS81 and gastric cancer.